The Inhibrx Management Team

Mark P. Lappe
Mark P. Lappe

Founder, Chief Executive Officer

Brendan P. Eckelman, Ph.D.
Brendan P. Eckelman, Ph.D.

Founder, EVP Chief Scientific Officer

Quinn Deveraux, Ph.D.
Quinn Deveraux, Ph.D.

Founder

Kelly Deck, C.P.A.
Kelly Deck, C.P.A.

Chief Financial Officer

Ashraf Amanullah, Ph.D.
Ashraf Amanullah, Ph.D.

EVP, Chief Technical Operations Officer

David Matly, M.B.A.
David Matly, M.B.A.

EVP, Chief Commercial Officer

Jeffrey Jensen
Jeffrey Jensen

EVP, Chief Clinical Development Officer

Carlos Bais, Ph.D.
Carlos Bais, Ph.D.

EVP, Translational Sciences

Leah Pollema, J.D.
Leah Pollema, J.D.

VP, General Counsel

David Kao, PharmD, M.B.A., RPh
David Kao, PharmD, M.B.A., RPh

VP, Regulatory Affairs

Vasily Andrianov, M.D.
Vasily Andrianov, M.D.

VP, Clinical Development and Medical Affairs

Robert Boothroyd, PharmD
Robert Boothroyd, PharmD

VP, Medical Affairs and Business Development

The Inhibrx Board

Mark P. Lappe

Chairman

Douglas G. Forsyth

Director

Jon Faiz Kayyem, Ph.D.

Director

Kimberly Manhard

Director

Kristiina Vuori, M.D., Ph.D.

Director

The INBRX-101 Scientific Advisory Board

Igor Barjaktarevic, M.D., Ph.D.

Mark Brantly, M.D.

Kenneth R. Chapman, M.D., MSc, FRCPC, FACP, FERS

Noel Gerry McElvaney, M.D., BCh, BAO, FRCPI, FRCPC

Robert A. Sandhaus, M.D., Ph.D., FCCP

James Stoller, M.D., M.S.